Pericytes have historically been a neglected cell type. Although they were first found in the late 19th century, there was a lack of significant research on them for the next century (19). The diverse population of pericytes, which can be challenging to distinguish, has impeded scientific progress on them. However, advances in technology and methodologies have facilitated the identification and examination of pericytes, leading to an exponential increase in pericyte research in the last 20 years. The findings from the in vivo and in vitro investigations (13–15) have suggested the involvement of pericytes in PD pathology though the extent of their contribution remains unclear.
The developments in iPSC-technology helped pericyte research as it provides an unlimited source of cells. The hiPSC-derived pericytes produced with the neural crest protocol from Faal et al. (17) have already been used in several studies and have been shown to possess similar properties compared to human brain vascular pericytes (HBVP). They have been shown to exhibit similar morphology to HBVPs (20) as well as expression of PDGFRβ, NG2, CD13, CD146, and αSMA comparable to HBVPs (17). Also, the functional properties of pericyte-like cells have been compared to HBVPs. In monocultures, hiPSC-derived pericytes showed similar proliferative response to PDGF-BB and PDGFRβ signaling inhibitor imatinib and they also responded to Endothelin-1, even though there was difference in maximum contraction and contraction time following the endothelin-1 exposure (20). In co-culture with brain microvessel endothelial cells (BMECs), the pericyte-like cells had similar effects on tube formation and transendothelial electrical resistance as the HBVPs (17). The difference between hiPSC-derived pericytes and HBVPs has also been studied at the transcriptomic level and even though there were clear difference between HBVPs and hiPSC-derived pericytes derived with two different protocols, the changes might be explained by differences in genetic background and possible immaturity of hiPSC-derived pericytes. Overall, hiPSC-derived pericyte-like cells derived with neural crest protocol seem to have high resemblance to HBVPs in expression of pericyte markers as well as functionally, and thus are a suitable model for studying pericytes.
We started this study by comparing two differentiation factors TGFβ3 and SB431542 for producing the pericyte-like cells to examine the impact of these factors on differentiation. Both differentiation factors produced cells expressing pericyte markers PDGFRβ and αSMA, the expression of which has been reported earlier in these cells(17) in addition to CD13 as well as pericyte associated genes confirming pericyte-like identity of the cells. And while TGFβ3 and SB431542 generated cells were similar in terms of their morphology and the presence of pericyte markers CD13, PDGFRβ, and αSMA proteins, RNA sequencing uncovered clear differences between the cells. We observed increased expression of pericyte markers and upregulation in pericyte associated pathways in TGFβ3 differentiated cells and thus TGFβ3 was chosen for later experiments.
We observed no significant differences in cell morphology or pericyte marker expression in ICC samples between SB431542 and TGFβ3 differentiated pericyte-like cells, as well as between healthy and PD lines. Both healthy and PD pericyte-like cells expressed LRRK2 and SNCA genes, showing no significant difference in expression levels. However, despite the expression of SNCA in the cells, α-synuclein remained absent. The absence of α-synuclein in the pericyte-like cells aligns with previous findings from in vitro cultures of primary human brain pericytes (13). Also, in permeability tests, we did not detect significant changes between healthy and PD lines. Accordingly, it seems that in basal conditions, healthy and PD pericyte-like cells are similar in morphology, expression of pericyte markers, and in their effect on barrier property.
At the transcriptomic level, healthy and PD pericytes were also very similar, with only 43 differentially expressed genes. However, we observed notable differences within those genes. Prominent alterations in PD lines included the decrease in the expression of maternally expressed genes 3 (MEG3) and − 8 (MEG8) as well as the changes in genes NDNF and GJA5, which negatively regulate angiogenesis. MEG3 and MEG8 are long noncoding RNAs that are known for their regulative roles in cell proliferation and migration. The studies with MEG8 have indicated cell type dependent effects on proliferation and migration. Even though multiple studies have demonstrated that MEG8 expression enhances proliferation and migration of cancer cells (21) as well as of vascular endothelial cells (22, 23), studies with vascular smooth muscle cells showed the opposite (24, 25). MEG3 has been associated with PD, as several studies have identified altered levels of MEG3 in PD patients. Specifically, two studies found lower levels of MEG3 in plasma (26, 27) while one study reported increased levels (28). Furthermore, there appears to be a correlation between the expression of MEG3 and LRRK2, as the overexpression of MEG3 resulted in an enhanced expression of LRRK2 in SH-SY5Y cells exposed to MPP+(27). Currently, there are only a few studies on the functioning of MEG3 and − 8 in pericytes. Considering our existing knowledge on MEG3 and MEG8, and the role of pericytes in vascular functions, investigating the specific mechanism by which MEG3 and MEG8 function in pericytes and ECs could provide useful insight into vascular changes identified in PD.
The transcriptome data also indicated increased expression of genes linked to inflammation in PD pericyte-like cells. Additionally, pathway analysis revealed alterations in processes related to the regulation of chemokine production and interaction between cytokines and cytokine receptors. Under basal conditions, the release of cytokines was comparable in both healthy and PD lines. However, when the cells were exposed to IL-1β, a pro-inflammatory cytokine known to be elevated in PD (29, 30), the secretion of sVCAM-1 and MCP-1 was significantly increased in PD lines compared to healthy lines. The impact of IL-1β on primary human brain pericytes has been previously investigated (31) with the similar finding that IL-1β exposure resulted in the release of sVCAM-1 and MCP-1. Clinical studies have shown that sVCAM-1 levels in plasma of the PD patients are higher than those of healthy individuals(32). These levels are also correlated with disease progression, particularly with motor impairment (32). In regards of MCP-1, there have been contradictory results about whether MCP-1 levels are elevated in PD. At least one study reported increased MCP-1 levels in cerebrospinal fluid of PD patients(33) while another study found no difference compared to healthy controls but suggested that the levels of MCP-1 might correlate with disease progression and motor dysfunction (34). sVCAM-1 is able to disrupt brain endothelial integrity and is also associated with tumor angiogenesis. On the other hand, MCP-1 plays a crucial role in inflammation by attracting inflammatory cells and enhancing the production of other inflammatory factors. Therefore, elevated amounts of sVCAM-1 and MCP-1 secreted by PD pericytes could result in heightened permeability of the BBB and an intensified inflammatory response. However, due to the total loss of barrier property in ECs exposed to IL-1β, we were unable to determine whether exposure to IL-1β would cause a different response in permeability in EC co-cultures with PD and healthy pericyte-like cells. Our results suggest that hiPSC-derived pericyte-like cells carrying the LRRK2 G2019S mutation exhibit a more reactive phenotype in pericytes. Similar changes in reactivity due to the LRRK2 G2019S mutation have been previously reported in glial cells, astrocytes and microglia, which are likewise activated during neuroinflammation (35–37). Yet, the impact of this mutation on pericytes has not been studied previously.
Pericyte migration and angiogenesis are closely related to each other, as the migration of pericytes is essential for the proper formation of new blood vessels. Prior research suggests that during the initial stages of angiogenesis, migration of pericytes from the vessel is necessary to initiate ECs sprouting and later to stabilize the newly formed vessels (38). Thus, we evaluated if changes in the transcriptome impacted the functionality of pericyte-like cells. The migration assay demonstrated impaired movement of PD pericyte-like cells both in their normal state and when exposed to inflammatory stimuli. Nevertheless, the migration speed of PD pericyte-like cells notably enhanced when exposed to pro-angiogenic molecules, specifically PDGF-BB, in contrast to unexposed or IL-1β exposed cells. Furthermore, it appears that PD lines require pro-angiogenic stimuli in order to achieve the same level of migration as pericyte-like cells from healthy lines.
Limitation of our study
Pericyte migration is important for normal angiogenesis. Hampered migration can alter angiogenesis and destabilize newly formed blood vessels. In this research, we examined only one pro-angiogenic molecule, but it would be advantageous to additionally investigate, for example, VEGF. VEGF is elevated in the brains of the PD patients and it could be examined if different concentrations lead to changes in pericyte-like cells between healthy and PD lines. We also did not test how cells would behave when exposed simultaneously to pro-inflammatory and pro-angiogenic stimuli. The study from Kang et al. has demonstrated that when pericytes are present, the antiangiogenic effect of TNFα on ECs can be turned into a pro-angiogenic effect, in the presence of the pro-angiogenic molecule VEGF(11). Thus, it is possible that combined exposure with PDGF-BB and IL-1β may have a distinct consequence on migration than just individual exposures with PDGF-BB and IL-1β.
In addition, we were not able to include an isogenic line in which the LRRK2 G2019S mutation has been corrected. The isogenic line with otherwise similar genome to PD line except for the LRRK2 gene would have allowed us to determine if the changes we see in the PD pericyte-like cells are specifically due to LRRK2 G2019S mutation. However, without isogenic lines we cannot exclude the possibility of other genetic factors contributing to these changes.